/PVLA
PVLA Stock - Palvella Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$99.73+3.63%
+$3.49 (+3.63%) • Dec 19
90
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+60.0%upside
Target: $159.57
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for PVLA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$98.73 – $100.73
TARGET (TP)$159.55
STOP LOSS$91.75
RISK/REWARD1:7.5
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.19
52W High$112.00
52W Low$11.17
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | N/A | N/A | $25.90M | $31.42M |
| Gross Profit | N/A | N/A | $23.12M | $29.05M |
| Gross Margin | N/A | N/A | 89.3% | 92.5% |
| Operating Income | $-14,095,000 | $-11,869,000 | $-43,474,000 | $-51,831,000 |
| Net Income | $-17,434,000 | $18.69M | $-33,277,000 | $-45,738,000 |
| Net Margin | N/A | N/A | -128.5% | -145.6% |
| EPS | $-7.83 | $14.74 | $-29.61 | $-56.69 |
Company Overview
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.
Visit WebsiteRating Distribution
Strong Buy
1
8%
Buy / Outperform
11
92%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
12 Bullish0 Neutral/Bearish
Price Targets
$79
Average Target
↓ 21.0% Downside
Now
$38
Low
$79
Average
$175
High
Based on 12 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 5th 2025 | BTIG Research | Initiation | Buy | $167 |
| December 4th 2025 | Craig Hallum | Initiation | Buy | $175 |
| November 19th 2025 | Raymond James | Upgrade | Strong Buy | $143 |
| September 9th 2025 | Oppenheimer | Initiation | Outperform | $85 |
| August 6th 2025 | Raymond James | Initiation | Outperform | $54 |
| July 21st 2025 | Truist | Initiation | Buy | $56 |
| April 9th 2025 | Chardan Capital Markets | Initiation | Buy | $50 |
| March 26th 2025 | Stifel | Initiation | Buy | $45 |
| March 7th 2025 | Scotiabank | Initiation | Sector Outperform | $50 |
| February 20th 2025 | Canaccord Genuity | Initiation | Buy | $39 |
| February 5th 2025 | TD Cowen | Initiation | Buy | $44 |
| December 26th 2024 | H.C. Wainwright | Initiation | Buy | $38 |
| December 18th 2024 | Cantor Fitzgerald | Initiation | Overweight | - |
Earnings History & Surprises
PVLABeat Rate
64%
Last 11 quarters
Avg Surprise
+108.9%
EPS vs Estimate
Beats / Misses
7/4
Last 12 quarters
Latest EPS
$-1.03
Q4 2025
EPS Surprise History
Q1 24
+61.4%
$-3.71vs$-9.60
Q2 24
+58.3%
$-2.00vs$-4.80
Q3 24
-15.0%
$-2.76vs$-2.40
Q4 24
-301.8%
$-2.19vs$-0.55
Q1 25
+1125.6%
$4.00vs$-0.39
Q2 25
+78.2%
$-0.74vs$-3.40
Q3 25
-10.3%
$-0.86vs$-0.78
Q4 25
-21.2%
$-1.03vs$-0.85
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 30, 2026 | $-0.96 | — | — | — |
Q4 2025 | Nov 11, 2025 | $-0.85 | $-1.03 | -21.2% | ✗ MISS |
Q3 2025 | Aug 14, 2025 | $-0.78 | $-0.86 | -10.3% | ✗ MISS |
Q2 2025 | May 15, 2025 | $-3.40 | $-0.74 | +78.2% | ✓ BEAT |
Q1 2025 | Mar 31, 2025 | $-0.39 | $4.00 | +1125.6% | ✓ BEAT |
Q4 2024 | Nov 13, 2024 | $-0.55 | $-2.19 | -301.8% | ✗ MISS |
Q3 2024 | Aug 14, 2024 | $-2.40 | $-2.76 | -15.0% | ✗ MISS |
Q2 2024 | May 16, 2024 | $-4.80 | $-2.00 | +58.3% | ✓ BEAT |
Q1 2024 | Mar 30, 2024 | $-9.60 | $-3.71 | +61.4% | ✓ BEAT |
Q4 2023 | Nov 15, 2023 | $-8.80 | $-8.70 | +1.1% | ✓ BEAT |
Q3 2023 | Aug 11, 2023 | $-12.54 | $3.62 | +128.9% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-14.68 | $-1.17 | +92.0% | ✓ BEAT |
Latest News
Truist Securities Maintains Buy on Palvella Therapeutics, Raises Price Target to $190
📈 PositiveBenzinga•Dec 16, 2025, 02:47 PM
Canaccord Genuity Maintains Buy on Palvella Therapeutics, Raises Price Target to $204
📈 PositiveBenzinga•Dec 16, 2025, 02:35 PM•Also:
Adagene, Palvella gain after FDA Fast Track Designations
📈 PositiveSeeking Alpha•Dec 16, 2025, 02:24 PM•Also:
TD Cowen Maintains Buy on Palvella Therapeutics, Raises Price Target to $133
📈 PositiveBenzinga•Dec 16, 2025, 02:06 PM
Palvella Therapeutics Granted FDA's Fast Track Designation To QTORIN Rapamycin To Treat Angiokeratomas
📈 PositiveBenzinga•Dec 16, 2025, 12:35 PM
Chardan Capital Maintains Buy on Palvella Therapeutics, Raises Price Target to $174
📈 PositiveBenzinga•Dec 16, 2025, 12:25 PM
HC Wainwright & Co. Maintains Buy on Palvella Therapeutics, Raises Price Target to $200
📈 PositiveBenzinga•Dec 15, 2025, 06:12 PM
Palvella Therapeutics Announces Phase 2 TOIVA Success With 73% Improvement On Overall Cutaneous Venous Malformations IGA In Topline Results
📈 PositiveBenzinga•Dec 15, 2025, 11:12 AM
Clear Street Initiates Coverage On Palvella Therapeutics with Buy Rating, Announces Price Target of $200
📈 PositiveBenzinga•Dec 5, 2025, 01:31 PM
BTIG Initiates Coverage On Palvella Therapeutics with Buy Rating, Announces Price Target of $167
📈 PositiveBenzinga•Dec 5, 2025, 12:46 PM
Craig-Hallum Initiates Coverage On Palvella Therapeutics with Buy Rating, Announces Price Target of $175
📈 PositiveBenzinga•Dec 4, 2025, 05:52 PM
Stifel Maintains Buy on Palvella Therapeutics, Raises Price Target to $145
📈 PositiveBenzinga•Nov 24, 2025, 05:35 PM•Also:
Palvella Therapeutics shares are trading higher after Raymond James upgraded the stock from Outperform to Strong Buy and raised its price target from $92 to $143.
📈 PositiveBenzinga•Nov 19, 2025, 05:36 PM•Also:
Raymond James Upgrades Palvella Therapeutics to Strong Buy, Raises Price Target to $143
📈 PositiveBenzinga•Nov 19, 2025, 12:47 PM•Also:
Canaccord Genuity Maintains Buy on Palvella Therapeutics, Raises Price Target to $148
📈 PositiveBenzinga•Nov 13, 2025, 09:01 PM•Also:
Chardan Capital Maintains Buy on Palvella Therapeutics, Maintains $110 Price Target
📈 PositiveBenzinga•Nov 13, 2025, 02:04 PM
Palvella Therapeutics Q3 EPS $(1.03) Misses $(0.83) Estimate
📉 NegativeBenzinga•Nov 11, 2025, 12:43 PM
Truist Securities Maintains Buy on Palvella Therapeutics, Raises Price Target to $105
📈 PositiveBenzinga•Nov 10, 2025, 05:02 PM
Chardan Capital Maintains Buy on Palvella Therapeutics, Raises Price Target to $110
📈 PositiveBenzinga•Nov 7, 2025, 07:29 PM
TD Cowen Maintains Buy on Palvella Therapeutics, Raises Price Target to $97
📈 PositiveBenzinga•Nov 6, 2025, 06:13 PM
Frequently Asked Questions about PVLA
What is PVLA's current stock price?
Palvella Therapeutics, Inc. (PVLA) is currently trading at $99.73 per share. The stock has moved +3.63% today.
What is the analyst price target for PVLA?
The average analyst price target for PVLA is $159.55, based on 1 analyst.
What sector is Palvella Therapeutics, Inc. in?
Palvella Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is PVLA's market cap?
Palvella Therapeutics, Inc. has a market capitalization of $1.18 billion, making it a small-cap company.
Does PVLA pay dividends?
No, Palvella Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABUS
Arbutus Biopharma Corporation
$4.43
Mkt Cap: $0.9B
EYPT
EyePoint Pharmaceuticals, Inc.
$17.43
Mkt Cap: $1.2B
GHRS
GH Research PLC
$12.96
Mkt Cap: $0.8B
KURA
Kura Oncology, Inc.
$9.84
Mkt Cap: $0.9B
NBTX
Nanobiotix S.A.
$22.13
Mkt Cap: $1.1B
PROK
ProKidney Corp.
$2.37
Mkt Cap: $0.3B
RZLT
Rezolute, Inc.
$1.77
Mkt Cap: $0.2B
SPRY
ARS Pharmaceuticals, Inc.
$10.49
Mkt Cap: $1.0B
SVRA
Savara Inc.
$6.05
Mkt Cap: $1.2B
TYRA
Tyra Biosciences, Inc.
$25.51
Mkt Cap: $1.4B
Explore stocks similar to PVLA for comparison